Nivestim®

BIOLOGICAL2 trials

Sponsors

Hospira, now a wholly owned subsidiary of Pfizer, Pfizer

Conditions

Chemotherapy-Induced NeutropeniaChemotherapy-induced Febrile Neutropenia (FN)Malignant HemopathySolid Tumors

Unknown Phase

Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents

CompletedNCT01574235

Hospira, now a wholly owned subsidiary of PfizerChemotherapy-induced Febrile Neutropenia (FN), Malignant Hemopathy, Solid Tumors

Start: 2011-10-31End: 2014-02-28Updated: 2015-07-28

Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study

TerminatedNCT02454530

PfizerChemotherapy-Induced Neutropenia

Start: 2014-09-30End: 2017-01-31Updated: 2019-06-28

Related Papers

Abstract P1-10-03: Biosimilar filgrastim in the treatment of patients with breast cancer undergoing neutropenia-inducing chemotherapy: A subanalysis of the NEXT study

Cancer Research2016-02-15

Safety of biosimilar filgrastim in elderly patients undergoing neutropenia-inducing chemotherapy: a subanalysis of the NEXT study.

Journal of Clinical Oncology2015-05-201 citations

Safety of biosimilar filgrastim in patients with breast cancer undergoing neutropenia-inducing chemotherapy: A subanalysis of the NEXT study.

Journal of Clinical Oncology2015-05-201 citations

Febrile neutropenia risk factors: A subanalysis of the NEXT study.

Journal of Clinical Oncology2015-05-20

Usage of biosimilar filgrastim: A subanalysis of the next study.

Journal of Clinical Oncology2014-11-01

Safety of biosimilar filgrastim in patients undergoing neutropenia-inducing chemotherapy: Next study.

Journal of Clinical Oncology2014-11-01

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.

2013-11-166 citations